natgillin/translations-raw huggingface dataset:
Nemdatine is not recommended for children and adolescents under the age of 18 years.
Nemdatine se ne preporučuje za djecu i adolescente mlađe od 18 godina.
Nemdatine is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Nemdatine se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
Nemdatine should be administered once a day and should be taken at the same time every day.
Nemdatine treba primjenjivati jedanput na dan i potrebno ga je uzimati svaki dan u isto vrijeme.
Neoadjuvant Treatment of Breast Cancer
Neoadjuvantno liječenje raka dojke
Neoclarityn contains desloratadine which is an antihistamine.
Neoclarityn sadrži desloratadin, koji je antihistaminik.
Neoclarityn desloratadine
Neoclarityn desloratadin
Neoclarityn has no or negligible influence on the ability to drive and use machines based on clinical trials.
Temeljem rezultata kliničkih ispitivanja Neoclarityn ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Neoclarityn is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
Neoclarityn je indiciran u odraslih i adolescenata u dobi od 12 ili više godina za ublažavanje simptoma povezanih s:
Neoclarityn is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:
Neoclarityn je indiciran u odraslih i adolescenata u dobi od 12 ili više godina, te u djece u dobi od 6 do 11 godina za ublažavanje simptoma povezanih s:
Neoclarityn is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:
Neoclarityn je indiciran u odraslih, adolescenata i djece starije od 1 godine za ublažavanje simptoma povezanih s:
Neoclarityn may be taken with or without a meal.
Neoclarityn se može uzeti uz ili bez obroka.
Neoclarityn oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap.
Neoclarityn oralna otopina dostupna je u bocama od 30, 50, 60, 100, 120, 150, 225 i 300 ml, sa sigurnosnim zatvaračem za djecu.
Neoclarityn oral solution with food, drink and alcohol
Neoclarityn oralna otopina s hranom, pićem i alkoholom
Neoclarityn orodispersible tablet contains aspartame
Neoclarityn raspadljive tablete za usta sadrže aspartam
Neoclarityn orodispersible tablet does not need to be taken with water or liquid.
Neoclarityn raspadljive tablete za usta ne trebaju se uzimati s vodom ili drugom tekućinom.
Neoclarityn orodispersible tablet with food, drink and alcohol
Neoclarityn raspadljive tablete za usta s hranom, pićem i alkoholom
Neocolipor
Neocolipor.
Neofordex 40 mg tablet dexamethasone
Neofordex 40 mg tableta deksametazon
Neofordex 40 mg tablets dexamethasone
Neofordex 40 mg tablete deksametazon
Neomycin Phenol red
neomicin fenolno crvenilo
neonatal (see section 4.6)
sindrom ustezanja od lijeka u novorođenčadi (vidjeti dio 4.6)
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6 – 17 the MRHD on a mg/m2 basis).
Neonatalna i juvenilna ispitivanja na štakorima i psima pokazala su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6 – 17 the MRHD on a mg/m2 basis).
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6- 17 the MRHD on a mg/m2 basis)
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjeramaishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis).
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x6-17 the MRHD on a mg/m2 basis).
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17- erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Neonatal calves less than 12 hours of age.
Novorođena telad starosti do 12 sati.
Neonatal growth was reduced in rats while exposed to Victoza, and persisted in the post­weaning period in the high dose group.
Neonatalni rast bio je smanjen u štakora tijekom izloženosti lijeku Victoza i to se zadržalo tijekom razdoblja nakon odvikavanja od sisanja u skupini na visokoj dozi lijeka.
Neonatal piglets derive passive immunity via ingestion of colostrum from vaccinated sows/gilts.
Novooprasena prasad će postići pasivni imunitet preko kolostruma cijepljenih krmača/nazimica .
Neonatal piglets derive passive immunity via ingestion of colostrum from vaccinated sows/gilts.
Novooprasena prasad će steći pasivni imunitet preko kolostruma od cijepljenih krmača/nazimica .
Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also called Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA),
Neonatalne multisistemske upalne bolesti, koja se naziva i kroničnim infantilnim neurokutanim artikularnim sindromom,
Neonates and infants are known to have diminished MetHb reductase activity compared to adults.
Neonatusi i dojenčad imaju smanjenu aktivnosti MetHb reduktaze u usporedbi s odraslima.
Neonates and infants from birth to less than 12 months of age with type 1 diabetes mellitus and children from birth to less than 10 years of age with type 2 diabetes mellitus on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset (see section 4.2 for information on paediatric use).
Novorođenčadi i dojenčadi od rođenja do dobi od manje od 12 mjeseci sa šećernom bolešću tipa 1 i u djece od rođenja do manje od 10 godina sa šećernom bolešću tipa 2, budući da se bolest ili stanje za koje je specifični lijek namijenjen ne javlja u navedenoj pedijatrijskoj podskupini (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Neonates and infants from birth to less than 12 months of age with type 1 diabetes mellitus.
Novorođenčadi i dojenčadi od rođenja do dobi od manje od 12 mjeseci sa šećernom bolešću tipa 1.
Neonates and infants under the age of 2 years (see section 4.4)
Novorođenčad i dojenčad ispod 2 godine starosti (vidjeti dio 4.4).
Neonates and young children up to 3 years old, because of the excipient benzyl alcohol (see section 4.4 for benzyl alcohol)
novorođenčad i mala djeca do 3 godine starosti zbog pomoćne tvari benzilni alkohol (vidjeti dio
Neonates exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
U novorođenčadi izloženoj antipsihoticima (uključujući olanzapin) tijekom trećeg tromjesečja trudnoće postoji rizik od nastanka nuspojava, uključujući ekstrapiramidalne simptome i/ili simptome ustezanja koji mogu, nakon poroda, varirati po težini i trajanju.
Neoplams
Novotvorine
Neoplasm
Novotvorine
neoplasm (tumour) progression new cancers of the bone marrow or blood, such as acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS)
progresija neoplazme (tumora) novi tumori koštane srži ili krvi, kao što su akutna mijeloična leukemija (ADL) ili mijelodisplastički sindrom (MDS)
Neoplasm benign, malignant and unspecified (incl. cysts and polyps)
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign*
Zloćudna novotvorina, plazmocitna leukemija, karcinom renalnih stanica, izraslina, Mycosis fungoides, dobroćudna novotvorina
Neoplasm progression
progresija neoplazme
Neoplasm with increased bleeding risk
neoplazma s povećanim rizikom od krvarenja
neoplasm with increased bleeding risk
novotvorina s povećanim rizikom od krvarenja
Neoplasms
Dobroćudne,
Neoplasms
Novotvorine
Neoplasms
podataka)
Neoplasms benign and malignant
Dobroćudne i zloćudne novotvorine
Neoplasms benign and malignant (incl cysts and polyps)
Dobroćudne i zloćudne
Neoplasms Benign,
Dobroćudne,
Neoplasms benign,
Dobroćudne, zloćudne i
Neoplasms Benign,
Dobroćudne, zloćudne i nespecificirane
Neoplasms Benign, Malignant and Unspecified
Dobroćudne, zloćudne i nespecificirane
Neoplasms benign, malignant and unspecified
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dobroćudne, zloćudne i nespecificirane novotvorevine (uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (Incl. cysts and polyps)
Dobroćudne, zloćudne i nespecifične novotvorine (uklj. ciste i polipe)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps): Uncommon: Non-melanoma skin cancers* (see section 4.4) Rare: Lymphoma, melanoma (see section 4.4)
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe): Manje često: ne-melanomski rak kože* (vidjeti dio 4.4) Rijetko: limfom, melanom (vidjeti dio 4.4)
Neoplasms benign, malignant and unspecified (includes cysts and polyps)
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
(uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant and unspecified (including cysts and polyps):
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe):
Neoplasms benign, malignant and unspecified (inl. cysts and polyps)
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant andunspecified(incl cysts and polyps)
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neoplasms benign, malignant, and unspecified
Dobroćudne, zloćudne i nespecificirane novotvorine
Neoplasms including lymphoproliferative disorders, skin cancers (melanomas and non- melanomas), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ (see section 4.4).
Novotvorine uključujući limfoproliferativne poremećaje, rak kože (melanomski i nemelanomski), sarkome (Kaposijev i ne-Kaposijev) te rak vrata maternice in situ (vidjeti dio 4.4.).
Neoplasms, benign, malignant and unspecified
Dobroćudne, zloćudne i nespecificirane novotvorine
Neoplasms, benign, malignant and unspecified
Neoplazma, dobroćudna, zloćudna i nespecifična
Neoplasms, benign, malignant and unspecified (incl cysts and polyps)*
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
Neopterin concentrations return to baseline after the two week dosing interval.
Koncentracije neopterina se vračaju na početno stanje nakon 2-tjednog intervala doziranja.
NeoRecormon 10,000 IU injection IV/SC use
NeoRecormon 10 000 IU injekcija i.v./s.c. primjena
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 10 000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 10,000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 10 000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 20,000 IU
NeoRecormon 30 000 IU
NeoRecormon 20,000 IU injection IV/SC use
NeoRecormon 20 000 IU injekcija i.v./s.c. primjena
NeoRecormon 20,000 IU solution for injection in pre-filled syringe
NeoRecormon 20 000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 20,000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 20 000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 2000 IU injection IV/SC use
NeoRecormon 2000 IU injekcija i.v./s.c. primjena
NeoRecormon 2000 IU solution for injection in pre-filled syringe
NeoRecormon 2000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 2000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 2000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 2000 IU, 3000 IU, 4000 IU,5000 IU, 6000 IU, 10,000 IU and 20,000IU
NeoRecormon 2000 IU, 3000 IU, 4000 IU,5000 IU, 6000 IU, 10 000 IU i 20 000 IU
NeoRecormon 30,000 IU
NeoRecormon 30 000 IU
NeoRecormon 30,000 IU injection IV/SC use
NeoRecormon 30 000 IU injekcija i.v./s.c. primjena
NeoRecormon 30,000 IU solution for injection in pre-filled syringe
NeoRecormon 30 000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 30,000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 30 000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 3000 IU injection IV/SC use
NeoRecormon 3000 IU injekcija i.v./s.c. primjena
NeoRecormon 3000 IU solution for injection in pre-filled syringe
NeoRecormon 3000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 3000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 3000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 4000 IU injection IV/SC use
NeoRecormon 4000 IU injekcija i.v./s.c. primjena
NeoRecormon 4000 IU solution for injection in pre-filled syringe
NeoRecormon 4000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 4000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 4000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 500 IU injection IV/SC use
NeoRecormon 500 IU injekcija i.v./s.c. primjena
NeoRecormon 500 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 500 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 5000 IU injection IV/SC use
NeoRecormon 5000 IU injekcija i.v./s.c. primjena
NeoRecormon 5000 IU solution for injection in pre-filled syringe
NeoRecormon 5000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 5000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 5000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon 6000 IU injection IV/SC use
NeoRecormon 6000 IU injekcija i.v./s.c. primjena
NeoRecormon 6000 IU solution for injection in pre-filled syringe
NeoRecormon 6000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 6000 IU solution for injection in pre-filled syringe Epoetin beta
NeoRecormon 6000 IU otopina za injekciju u napunjenoj štrcaljki epoetin beta
NeoRecormon contains phenylalanine and sodium
NeoRecormon sadrži fenilalanin i natrij
NeoRecormon contains phenylalanine, benzyl alcohol and sodium
NeoRecormon sadrži fenilalanin, benzilni alkohol i natrij
NeoRecormon dosing
Doziranje lijeka NeoRecormon
NeoRecormon injections can then be given by a trained nurse, doctor or other professional.
Injekcije lijeka NeoRecormon može Vam dati educirana medicinska sestra, liječnik ili neki drugi zdravstveni djelatnik.
NeoRecormon injections can then be given by a trained nurse, doctor or other professional. (See instruction for use at the end of this leaflet)
Injekcije lijeka NeoRecormon može Vam dati educirana medicinska sestra, liječnik ili neki drugi zdravstveni djelatnik. (Vidjeti upute za primjenu na kraju ove upute)
NeoRecormon is indicated for:
NeoRecormon je namijenjen za:
NeoRecormon Multidose 50,000 IU lyophilisate and solvent for solution for injection
NeoRecormon Multidose 50 000 IU liofilizat i otapalo za otopinu za injekciju
NeoRecormon Multidose 50,000 IU lyophilisate for injection IV/SC use
NeoRecormon Multidose 50 000 IU liofilizat za injekciju i.v./s.c. primjena
NeoRecormon should be administered by the subcutaneous route to patients with anaemia (e.g. haemoglobin concentration ≤ 10g/dl (6.2 mmol/l)).
Bolesnicima koji boluju od anemije NeoRecormon treba davati supkutano (npr. koncentracija hemoglobina ≤ 10 g/dl (6,2 mmol/l)).
NeoRecormon should be administered by the subcutaneous route to patients with anaemia (e.g. haemoglobin concentration ≤ 10g/dl (6.2 mmol/l).
Bolesnicima koji boluju od anemije NeoRecormon treba davati supkutano (npr. koncentracija hemoglobina ≤ 10 g/dl (6,2 mmol/l)).
NeoRecormonPremature infants who have already been transfused by the start of treatment with NeoRecormon are not likely to benefit as much as untransfused infants.
Nedonoščad koja je prethodno primila transfuziju, najvjerojatnije neće imati onoliku korist od liječenja lijekom NeoRecormon kao nedonoščad koja nije primila transfuziju.
NEOSPHERE is a phase II, multicentre, multinational randomized controlled trial with Perjeta and was conducted in 417 adult female patients with newly diagnosed, early, inflammatory or locally advanced HER2-positive breast cancer (T2-4d; primary tumour > 2cm in diameter) who had not received prior trastuzumab, chemotherapy or radiotherapy.
NEOSPHERE je multicentrično, multinacionalno randomizirano, kontrolirano ispitivanje lijeka Perjeta faze II, u kojem je sudjelovalo 417 odraslih bolesnica s novodijagnosticiranim, ranim, upalnim ili lokalno uznapredovalim HER2 pozitivnim rakom dojke (T2-4d; promjer primarnog tumora > 2 cm) koje prethodno nisu bile liječene trastuzumabom, kemoterapijom ni radioterapijom.
neovascular (wet) age-related macular degeneration (wet AMD), impaired vision due to macular oedema secondary to retinal vein occlusion (branch RVO (BRVO) or central RVO (CRVO)), impaired vision due to diabetic macular oedema (DME), impaired vision due to myopic choroidal neovascularisation (myopic CNV).
neovaskularna (vlažna) senilna makularna degeneracija (vlažni AMD), oštećena funkcija vida zbog makularnog edema kao posljedice okluzije retinalne vene (okluzija ogranka retinalne vene (BRVO) ili okluzija centralne retinalne vene (CRVO), oštećena funkcija vida zbog dijabetičkog makularnog edema (DME), oštećena funkcija vida zbog neovaskularizacije žilnice kod kratkovidnosti (miopijski CNV).
Neovii Biotech GmbH Am Haag 6-7
Neovii Biotech GmbH Am Haag 6- 7
Neparvis 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Neparvis 24 mg/26 mg filmom obložene tablete su ljubičasto bijele ovalne tablete s oznakom „NVR“ s jedne strane i „LZ“ s druge strane.
Neparvis 24 mg/26 mg film-coated tablets EU/1/16/1103/001
Neparvis 24 mg/26 mg filmom obložene tablete EU/1/16/1103/001
Neparvis 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Neparvis 24 mg/26 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171)
Neparvis 24 mg/26 mg film-coated tablets Neparvis 49 mg/51 mg film-coated tablets Neparvis 97 mg/103 mg film-coated tablets
Neparvis 24 mg/26 mg filmom obložene tablete Neparvis 49 mg/51 mg filmom obložene tablete Neparvis 97 mg/103 mg filmom obložene tablete
Neparvis 24 mg/26 mg film-coated tablets Neparvis 49 mg/51 mg film-coated tablets Neparvis 97 mg/103 mg film-coated tablets sacubitril/valsartan
Neparvis 24 mg/26 mg filmom obložene tablete Neparvis 49 mg/51 mg filmom obložene tablete Neparvis 97 mg/103 mg filmom obložene tablete sakubitril/valsartan
Neparvis 49 mg/51 mg film-coated tablets EU/1/16/1103/002-004
Neparvis 49 mg/51 mg filmom obložene tablete EU/1/16/1103/002-004
Neparvis 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Neparvis 49 mg/51 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171)
Neparvis 97 mg/103 mg film-coated tablets EU/1/16/1103/005-007
Neparvis 97 mg/103 mg filmom obložene tablete EU/1/16/1103/005-007
Neparvis 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171)
Neparvis 97 mg/103 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171)
Neparvis contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Neparvis sadrži valsartan pa se stoga ne smije primjenjivati zajedno s drugim lijekom koji sadrži ARB (vidjeti dio 4.4).
Neparvis contains valsartan, and therefore should not be co-administered with another ARB containing product (see sections 4.2 and 4.5).
Neparvis sadrži valsartan i stoga se ne smije primjenjivati zajedno s drugim lijekom koji sadrži ARB (vidjeti dijelove 4.2 i 4.5).
Neparvis must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy.
Neparvis se ne smije započinjati do 36 sati nakon uzimanja zadnje doze terapije ACE inhibitorom.
Neparvis must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Primjena Neparvisa ne smije se započinjati do 36 sati nakon uzimanja zadnje doze terapije ACE inhibitorom.
Neparvis should not be co-administered with an ACE inhibitor or an ARB.
Neparvis se ne smije primjenjivati istodobno s ACE inhibitorom ili ARB-om.
NePhar - Farma, Lda
92110 Clichy France
Nephritis
nefritis